Endologix, Inc. (NASDAQ:ELGX) traded down 0% during trading on Thursday . The stock traded as low as $3.75 and last traded at $4.05. 1,005,530 shares traded hands during trading, an increase of 26% from the average session volume of 798,262 shares. The stock had previously closed at $4.05.
Several equities research analysts recently commented on the company. Piper Jaffray Companies restated an “overweight” rating on shares of Endologix in a research report on Tuesday, December 12th. Royal Bank of Canada cut their target price on Endologix from $5.00 to $4.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 8th. JPMorgan Chase & Co. lowered Endologix from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. ValuEngine lowered Endologix from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, BidaskClub lowered Endologix from a “buy” rating to a “hold” rating in a research report on Friday, December 15th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. Endologix has a consensus rating of “Hold” and an average price target of $5.41.
The stock has a market cap of $337.57, a price-to-earnings ratio of -5.06 and a beta of 0.42. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.13. The business had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.91 million. Endologix had a negative return on equity of 52.18% and a negative net margin of 41.60%. The company’s quarterly revenue was down 7.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) earnings per share. equities analysts forecast that Endologix, Inc. will post -0.61 earnings per share for the current year.
A number of large investors have recently made changes to their positions in ELGX. Schwab Charles Investment Management Inc. boosted its holdings in Endologix by 10.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock worth $1,562,000 after acquiring an additional 30,429 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Endologix by 11.5% in the second quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock worth $529,000 after acquiring an additional 11,200 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Endologix by 40.8% in the second quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock worth $967,000 after acquiring an additional 57,675 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in Endologix by 48.5% in the second quarter. TIAA CREF Investment Management LLC now owns 324,193 shares of the medical instruments supplier’s stock worth $1,576,000 after acquiring an additional 105,895 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its holdings in Endologix by 128.1% in the second quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the medical instruments supplier’s stock worth $170,000 after acquiring an additional 19,600 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: “Endologix (ELGX) Shares Down 0%” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/22/endologix-elgx-shares-down-0.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.